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Genetically altered mice have been proposed
as adjuncts or replacements for conventional
rodents in 2-year chemical carcinogenesis
assays. Assays involving these mice hold
promise for being more rapid and less expen-
sive than traditional 2-year studies and in
theorymaybe directly relevant to humans in
that the mice are genetically engineered to
possess alterations in genes known to be
involved in many human cancers. For the
past several years, an effort has been under
way at the NIEHS to evaluate several
promising transgenic or genetically altered
mouse lines for carcinogen identification and
assessment. Two lines have received particu-
lar attention; the p53+1- heterozygote pos-
sesses only one functional copy of the p53
tumor suppressor gene in all cells. These
mice rapidly develop tumors when exposed
to mutagenic carcinogens. The other line,
the Tg.AC, was produced by pronuclear
injection of a v-Ha-ras gene under the con-
trol of the zeta-globin promoter. The pres-
ence of this oncogene confers on skin and
certain other tissues an enhanced susceptibil-
ity to the development oftumors in response
to physical wounding or to mutagenic or
nonmutagenic chemical carcinogens. A third
line (H-ras2), developed inJapan, has multi-
ple copies ofthe human ras gene in all cells
(1). This line has been evaluated for response
to manyknown carcinogens and several non-
carcinogens byJapanese researchers, and lim-
ited confirmatory studies are under waywith
this model at the NIEHS. Results from the
NTP/NIEHS "transgenic" studies to date
were reviewed by the NTP Board of
Scientific Counselors (BSC) on 5 February
1998 (2). A report from this review raised
several concerns and recommendations. It is
important to address these and other issues
that have arisen as the NTP attempts to
appropriately integrate genetically altered
mouse models into a scientifically valid
research and testingstrategy.
Many of the recent findings from
NIEHS/NTP studies of these models are
reported in a current issue of the journal
Toxicologic Pathology (3). These reports
cover the theoretical bases for the selection
ofthese models as potentially useful chem-
ical carcinogenesis screens, and examine
the molecular events required to trigger
tumorigenesis in the Tg.AC model.
Descriptions of these reports and an
update on the overall concordance between
the results of 2-year rodent studies with
results accumulated with the transgenic
models were presented to the BSC.
At the time of the BSC review, results
were available from NIEHS/NTP studies
on 38 chemicals with the Tg.AC and/or
p53+1- models, along with previously
reported findings from Japan with 18
chemicals studied in the Hras2 model. For
most studies, the doses used in the geneti-
cally altered mice were the same as those
used in the 2-year assays. Concordance was
defined as a positive result in any genetical-
ly altered model for a positive rodent or
human carcinogen, or negative results in all
genetically altered assays for a noncarcino-
gen. Not all chemicals were studied in all
models, but ofthe 38 chemicals studied at
the NIEHS/NTP, there were 13 results
that were considered nonconcordant.
Examination ofthe 13 discordant results
revealed some similarities that may illustrate
some general properties ofthe current mod-
els under evaluation. There were 11 chemi-
cals that produced tumors in rodents in the
2-year assays that were not detected as car-
cinogens in the genetically altered mouse
assays. For two of the chemicals, the single
tumor response in the 2-year study was
hepatocellular neoplasms in the B6C3F1
mouse. This tumor is frequently increased
in chemical carcinogenesis studies and is a
common spontaneous neoplasm in this
strain. For four others, mouse liver tumors
were accompanied by tumors of the rat or
mouse kidney or mouse adrenal gland in the
conventional bioassays. One chemical pro-
duced tumors in the rat nasal cavity and
mouse kidney in 2-year studies. One non-
mutagenic chemical was found negative in
the p53+1- mouse, an expected result, and
has not been studied in the Tg.AC or Hras2
models, which may respond to this carcino-
gen. Three multisite and/or multispecies car-
cinogens were also not detected bythe genet-
ically altered models, and the reasons for
these discordant results are under further
study. In two cases, a tumorigenic response
was obtained in a genetically altered mouse
model with a chemical considered negative
in traditional rodent studies (seven chemicals
were studied). One of these chemicals pro-
duced a lesion of questionable neoplastic
character in the TgAC mouse (myelodyspla-
sia). Perhaps the most important result from
this data review was that ofthe eight chemi-
cals tested that are recognized as known
human carcinogens, all eight were identified
as carcinogens in thegenetically altered mice.
The conclusions from this review were
that the new models performed largely
according to predictions; they identified all
known human carcinogens and most ofthe
multisite/multispecies rodent carcinogens;
they consistently failed to identify rodent
carcinogens that induced tumors at only a
few selected sites in 2-year studies; and final-
ly, while false positives did occur, the overall
tendency to miss certain chemicals, which
were identified as rodent carcinogens in the
2-year assay, did not support the notion that
the genetically altered mice were overly sen-
sitive to chemical carcinogens.
The BSC response to the results and
interpretations of these studies was mixed.
While the BSC believed that it was appro-
priate for the NTP to attempt to integrate
new models into a research and testing
framework and that the selection of the
p53+1- model was justified, the use of the
Tg.AC model was questioned. Responding
to research findings demonstrating that
chemicals producing a neoplastic response
in this mouse do so through activation ofa
zeta-globin promoter region on the v-Ha ras
transgene, board members questioned the
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conceptual relationship between the ability
to activate this specific promoter, with the
broader ability to induce cancer. TheTg.AC
was described aswidelyperceived as a tumor
promotion model and, if true, would be
unable to distinguish between complete car-
cinogens and tumor promoters. Other con-
cerns raised bythe BSC induded thegeneral
lack of information on dose response in
these initial assessments, the lack ofcompar-
ative toxicokinetic data in genetically altered
versus wild type mice, and the lack of a
more complete understanding for the rea-
sons why chemicals inducing tumors in cer-
tain tissue sites in the 2-year assay were
missed bythe newmodels.
The BSC also recommended that the
NTP should continue to develop a research
strategy for the next phase ofdevelopment
of these and other transgenic models that
may emerge as promising general chemical
carcinogen screens or as models for human
cancers occurring at sites which are infre-
quently seen in traditional 2-year rodent
studies. Noting that only three chemicals
have been shown to induce brain tumors
and no chemicals have induced prostate
tumors in rodents in the NTP/NCI data-
base, the BSC suggested that models incor-
porating disabled genes commonlyfound in
human tumors at these sites, and perhaps
others such as the colon, may be a useful
part ofan overall chemical testingstrategy.
An additional BSC charge to the NTP
was to begin to address how the findings
from geneticallyaltered mouse models could
be used in risk assessment. Cancer risk
assessment models may need to be modified
to accommodate the responses in genetically
altered mice. Clearly the characteristics of
Co. uin fromiheNPevla
tumor response would be expected to differ
in animals harboring a lesion in an early (H-
ras?) versus late (p53?) cancer gene. It is con-
ceivable that certain of these new models
will mimic sensitive human subpopulations
and, as such, represent a superior tool with
which unique human risks could be identi-
fied andjudged.
Many of the concerns of the BSC are
shared by the NIEHS/NTP and are being
addressed in ongoing studies. For example,
the findings that TCDD and diethylstilbe-
strol (DES) induced skin papillomas in the
Tg.AC mouse are being followed up with
studies examining in detail the dose-
response relationships for this response.
Tumor dose-response characteristics in the
Tg.AC mouse can be directlycomparedwith
the results from traditional bioassays and
with the doses of DES known to result in
human cancers. These kinds ofstudies will
begin to reveal howthese models can be used
in risk assessment. Other chemicals with
dioxinlike activity are being evaluated in the
Tg.AC model in hopes that cancer potency
can be quantitatively related to other dioxin-
like actions and that additive, synergistic, or
antagonistic tumor responses to mixtures of
these chemicals can be assessed. It is likely
that the tumor responses to TCDD and per-
haps DES in genetically altered mice are
through receptor activation, similar to their
actions in conventional animals. The dose
response for activation ofthe aryl hydrocar-
bon and estrogen receptors in comparison to
activation ofthe zeta-globin promoter in the
Tg.AC mouse need to be examined.
Interesting studies could also be performed
with DES in a possible cross between the
Tg.AC and the ERKO (estrogen receptor
rn of"transgeniC moue models for
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red mue moesb sdi rs seset
knock out) mouse line developed by K.S.
Korach at the NIEHS. The possibilities pre-
sented by theTg.AC mouse forstudying the
interactions ofsignalingpathways in receptor
mediated tumorigenesis appeargreat.
Efforts are also under way in response
to the question ofcomparative toxicokinet-
ics in genetically altered and wild-type
mice. There is little reason to assume that
the p53+1- or Tg.AC models would differ
in basic metabolic capacities from normal
mice, and in fact studies showing similarity
in many enzyme activities central to chemi-
cal metabolism in genetically altered and
wild-type mice have recently been pub-
lished in abstractform (4).
The NIEHS/NTP believes it is very
important to further study and understand
the apparent inabilityofthe current models
to detect all ofthe rodent carcinogens test-
ed and why the tested models seem to be
"blind" to carcinogens producing tumors at
certain sites. This seeming deficiencyofthe
new models may actually be an advantage
if the tumors missed are, for any reason,
not predictive of human responses.
Alternatively, the findings may suggest crit-
ical insensitivities of the new models to
potentially important human health risks.
A number ofpossibilities are being consid-
ered. For example, although the ras and
p53 genes are clearly altered in tumors in
many organs in rodents and humans, many
tumors arise without alterations in these
genes, and chemicals that act through path-
ways independent of ras or p53 may not
cause an accelerated tumor onset in these
models. Another important consideration
involves the degree to which strain-specific
characteristics of tumor development may
influence the response to expression ofneo-
plasia in a genetically altered mouse. A pre-
sumption underlying the development of
these models was that the strain-specific
susceptibility or resistance to expression of
spontaneous tumors, or to chemically
induced tumors that appear strain- or
species-specific, would be avoided in genet-
ically altered mouse assays (5). This was
held as an advantage ofthe models and was
based on two assumptions. First, the 6-
month duration ofthe studieswould be too
short for expression oftumors unrelated to
the genetic alteration, and second, strain-
specific influences on the expression of
oncogene or suppressor gene-related tumors
would be minimal. The fact that certain
multisite, multispecies rodent carcinogens
were notfound to be tumorigenic in geneti-
cally altered mice suggests that these
assumptions maynotbeentirelycorrect.
Harvey et al. (6) showed that strains of
mice of both low and high spontaneous
lymphoma background, when made
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homozygous for the p53 null allele had
enhanced spontaneous expression of lym-
phoma compared to wild-type mice.
Another tumor type, teratocarcinoma,
which is uncommon in any strain ofmice,
developed rapidly in p53-I- mice of one
strain but not the other. This experiment
gave evidence for a suppressor gene-related
effect outweighing strain-specific influences
on lymphoma incidence, as well as strain-
specific influences enhancing or completely
repressing the development of teratocarci-
nomas. We are unaware of similar studies
of strain-specific influences on chemically
induced tumors in genetically altered mice.
Until these studies are done, it is not possi-
ble to determine whether the rodent car-
cinogens missed by the new mouse models
represent strain-specific influences or sim-
ply were due to use of an improper study
duration or dose.
Clearly genetically altered mouse mod-
els hold great promise in carcinogenesis
research and testing. The challenge facing
the NTP is to design studies that address
the concerns and opportunities outlined
above while preserving sufficient resources
to provide information from traditional
prechronic and 2-year rodent assays. The
program is currently looking into ways in
which genetically altered mouse assays
could replace certain prechronic studies. In
this way, ifthe results from the genetically
altered mice were not sufficient to draw
conclusions on the carcinogenic potential
of a chemical or to fully characterize risk,
information would at least be available to
allow selection of doses for a conventional
2-year assay, which could begin immediate-
ly ifneeded.
Many other studies using genetically
altered mouse models are under way at the
NIEHS/NTP. These, along with studies
being done as part of a cooperative
International Life Sciences Institute-coordi-
nated program within the pharmaceutical
industry, in partnership with government
agencies, should soon provide a much
expanded dataset ofalternative assay results
on which decisions about their further use
can be based. Many NIEHS staffhave con-
tributed to these efforts and deserve much
credit for bringing these new mechanistical-
ly based models to where they are today
U.C. Barrett, R. Cannon, R. Chhabra, J.
Dunnick, W. Eastin, J. French, G. Lucier,
R. Maronpot, J. Mahler, G.N. Rao, M.
Shelby, J. Spalding, R. Tennant, K.
Tindall, S. Stasiewicz, and M. Vallant).
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